immune and inflammatory responses mediated by cytokines, play important roles in the pathophysiology of asthma. these responses are associated with overexpression of th2 cytokines such as il-4 and il-13. these two cytokines use common receptors for signaling that lead to identical immunological effects and regulation of the th1/th2 balance. the aim of this study was to determine whether patient...

Lebrikizumab (lebri) is a novel, monoclonal antibody that selectively targets interleukin (IL)-13 and prevents formation of the IL-13 receptor alpha 1 (Rα1)/IL-4 (Rα) heterodimer signaling complex. A previous crystal structure report showed lebri does not interfere with binding to Receptor 2 (Ra2) decoy receptor. In contrast, other antibodies tralokinumab cendakimab had been reported inhibit bo...

Tralokinumab, a fully human monoclonal antibody specifically targeting the IL-13 cytokine, has demonstrated clinical efficacy and safety in patients with moderate-to-severe atopic dermatitis. Tralokinumab binds high affinity which prevents interaction of IL-13Ra1 thereby inhibits signaling through IL-13Ra1/IL-4Ra receptor complex. Similarly, tralokinumab-bound cannot bind to IL-13Ra2, proposed ...